Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial

<p>Supplementary Figure 1. Planned exploratory analyses by study drug for selumetinib, vistusertib and capivasertib.</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Fabrice Barlesi (15045504) (author)
Altres autors:	Pascale Tomasini (4354063) (author), Maryam Karimi (7168769) (author), Stefan Michiels (108030) (author), Judith Raimbourg (15033410) (author), Catherine Daniel (7119086) (author), Henri Janicot (15019596) (author), Anne Madroszyk (15033398) (author), Clarisse Audigier-Valette (15045507) (author), Elisabeth Quoix (321740) (author), Julien Mazieres (15013412) (author), Denis Moro-Sibilot (15033407) (author), Eric Dansin (5576408) (author), Olivier Molinier (15019590) (author), Hugues Morel (15033419) (author), Eric Pichon (15033425) (author), Alexis Cortot (15045510) (author), Josiane Otto (6553544) (author), François Chomy (635983) (author), Pierre-Jean Souquet (3629372) (author), Nicolas Cloarec (15045513) (author), Etienne Giroux-Leprieur (385865) (author), Ivan Bieche (15045516) (author), Ludovic Lacroix (15030059) (author), Sandrine Boyault (9337805) (author), Valery Attignon (15045519) (author), Isabelle Soubeyran (515223) (author), Alain Morel (11665966) (author), Alicia Tran-Dien (14210462) (author), Alexandra Jacquet (14952799) (author), Filippo Gustavo Dall'Olio (15045522) (author), Marta Jimenez (14952288) (author), Jean-Charles Soria (15045525) (author), Benjamin Besse (3497516) (author)
Publicat:	2025
Matèries:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Drug Targets Immunotherapy Checkpoint blockade Lung Cancer Precision Medicine
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
per: Fabrice Barlesi (15045504)
Publicat: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
per: Fabrice Barlesi (15045504)
Publicat: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
per: Fabrice Barlesi (15045504)
Publicat: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
per: Fabrice Barlesi (15045504)
Publicat: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
per: John A. Ligon (15024477)
Publicat: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
per: Roger Li (17078665)
Publicat: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
per: Michelle L. Mierzwa (14963463)
Publicat: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
per: Qingsheng Xu (17078830)
Publicat: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
per: Qingsheng Xu (17078830)
Publicat: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
per: Giuseppe Basile (15051269)
Publicat: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
per: Andrés Elía (15055031)
Publicat: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
per: Andrés Elía (15055031)
Publicat: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
per: Andrés Elía (15055031)
Publicat: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
per: Andrés Elía (15055031)
Publicat: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
per: Andrés Elía (15055031)
Publicat: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
per: James S. Wilmott (15008931)
Publicat: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
per: James S. Wilmott (15008931)
Publicat: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
per: Nam Q. Bui (14958210)
Publicat: (2025)

Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
per: Steven B. Maron (15044607)
Publicat: (2025)

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
per: Samuel Rosner (15054884)
Publicat: (2025)

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
per: Kristoffer Staal Rohrberg (15009138)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ut5sffk64a0r5smu9e7ict5b5o